Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:30 | 2026-04-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $105.21 | 11,430 | $1,202,526 | 85,533 | -11.8% |
| 2026-04-03 20:53 | 2026-04-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer; EVP and Chief Legal Officer | Pharmaceutical Preparations | SALE | $449.17 | 978 | $439,288 | 21,833 | -4.3% |
| 2026-04-03 20:10 | 2026-04-01 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $18.64 | 5,727 | $106,751 | 125,373 | -4.4% |
| 2026-04-03 20:12 | 2026-04-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer; CHIEF MEDICAL OFFICER | Pharmaceutical Preparations | SALE | $32.66 | 1,838 | $60,029 | 38,864 | -4.5% |
| 2026-04-03 20:07 | 2026-04-01 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $17.81 | 8,820 | $157,084 | 0 | -100.0% |
| 2026-04-03 20:01 | 2026-04-01 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | Pharmaceutical Preparations | SALE | $777.27 | 100 | $77,727 | 17,603 | -0.6% |
| 2026-04-03 21:00 | 2026-04-02 | CAPR | CAPRICOR THERAPEUTICS, INC. | Sabar Karimah Es | Director | Pharmaceutical Preparations | OPT+S | $32.00 | 7,529 | $240,928 | 0 | -100.0% |
| 2026-04-03 20:07 | 2026-04-01 | INSM | INSMED Inc | Adsett Roger | Officer; Chief Operating Officer | Pharmaceutical Preparations | OPT+S | $164.63 | 88,060 | $14,497,652 | 106,810 | -45.2% |
| 2026-04-04 01:29 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $49.34 | 7,500 | $370,076 | 97,994 | -7.1% |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $50.00 | 7,958 | $397,900 | 0 | -100.0% |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $49.33 | 15,000 | $739,913 | 627,540 | -2.3% |
| 2026-04-03 23:46 | 2026-04-02 | IMNM | Immunome Inc. | Rosett Max | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $21.92 | 65,000 | $1,424,917 | 54,037 | -54.6% |
| 2026-04-03 23:48 | 2026-04-02 | IMNM | Immunome Inc. | Higgins Jack | Officer; Chief Scientific Officer | Pharmaceutical Preparations | SALE | $21.64 | 9,438 | $204,238 | 22,000 | -30.0% |
| 2026-04-03 22:17 | 2026-04-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | Director, Officer; CHIEF EXECUTIVE OFFICER | Pharmaceutical Preparations | OPT+S | $3.48 | 26,858 | $93,466 | 793,549 | -3.3% |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer; See Remarks | Pharmaceutical Preparations | OPT+S | $20.39 | 9,910 | $202,065 | 59,761 | -14.2% |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $20.39 | 5,199 | $106,008 | 32,558 | -13.8% |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $20.39 | 5,576 | $113,695 | 1,125,279 | -0.5% |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer; Chief Legal Officer | Pharmaceutical Preparations | OPT+S | $20.39 | 4,194 | $85,516 | 24,590 | -14.6% |
| 2026-04-03 21:59 | 2026-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer; See Remarks | Pharmaceutical Preparations | OPT+S | $20.39 | 9,614 | $196,029 | 120,619 | -7.4% |
| 2026-04-03 21:45 | 2026-04-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer; See Remarks | Pharmaceutical Preparations | SALE | $5.99 | 16,667 | $99,859 | 1,209,840 | -1.4% |
| 2026-04-03 21:46 | 2026-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | Pharmaceutical Preparations | SALE | $23.88 | 10,000 | $238,801 | 39,744 | -20.1% |
| 2026-04-03 21:09 | 2026-04-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | Pharmaceutical Preparations | SALE | $190.50 | 6,000 | $1,143,010 | 384,682 | -1.5% |
| 2026-04-03 21:20 | 2026-04-01 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer; CHIEF TECHNICAL OPS OFFICER | Pharmaceutical Preparations | SALE | $69.04 | 52,003 | $3,590,240 | 60,137 | -46.4% |
| 2026-04-03 21:06 | 2026-04-02 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | Pharmaceutical Preparations | BUY | $2.10 | 713,800 | $1,498,980 | 3,288,539 | +27.7% |
| 2026-04-03 20:05 | 2026-04-01 | EBS | Emergent BioSolutions Inc. | Williams Paul Anthony | Officer; SVP, Products Business | Pharmaceutical Preparations | SALE | $8.44 | 4,000 | $33,760 | 62,681 | -6.0% |
| 2026-04-03 19:13 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $16.00 | 679 | $10,864 | 3,622 | -15.8% |
| 2026-04-03 19:14 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $16.96 | 15,959 | $270,593 | 17,338 | -47.9% |
| 2026-04-03 13:00 | 2026-04-01 | ERAS | Erasca, Inc. | Garner Ebun | Officer; Chief Legal Officer | Pharmaceutical Preparations | OPT+S | $16.40 | 80,000 | $1,312,000 | 25,076 | -76.1% |
| 2026-04-02 21:58 | 2026-04-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer; EVP & CFO | Pharmaceutical Preparations | SALE | $48.33 | 34,791 | $1,681,512 | 32,916 | -51.4% |
| 2026-04-02 20:39 | 2026-04-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $12.95 | 2,500 | $32,375 | 119,010 | -2.1% |
| 2026-04-02 21:12 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Neal James R | Director | Pharmaceutical Preparations | BUY | $2.54 | 789 | $2,000 | 818 | +2,720.7% |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer; CHIEF EXECUTIVE OFFICER | Pharmaceutical Preparations | OPT+S | $30.93 | 60,000 | $1,855,842 | 432,886 | -12.2% |
| 2026-04-02 20:29 | 2026-04-01 | BMY | BRISTOL MYERS SQUIBB CO | Elkins David V | Officer; EVP, Chief Financial Officer | Pharmaceutical Preparations | SALE | $61.67 | 30,000 | $1,850,016 | 159,248 | -15.9% |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer; Chief Legal Officer and GC | Pharmaceutical Preparations | OPT+S | $30.00 | 10,000 | $300,000 | 105,211 | -8.7% |
| 2026-04-03 01:00 | 2026-03-31 | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% owner | Pharmaceutical Preparations | SALE | $3.34 | 5,880,415 | $19,636,470 | 10,265,297 | -36.4% |
| 2026-04-03 00:09 | 2026-04-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer; President, R&D | Pharmaceutical Preparations | OPT+S | $21.20 | 27,000 | $572,478 | 112,622 | -19.3% |
| 2026-04-02 23:43 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | Pharmaceutical Preparations | SALE | $202.23 | 467 | $94,440 | 42,253 | -1.1% |
| 2026-04-02 23:43 | 2026-04-02 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer; EVP, Chief Human Resources Ofc | Pharmaceutical Preparations | SALE | $74.05 | 6,193 | $458,613 | 16,348 | -27.5% |
| 2026-04-02 23:43 | 2026-04-01 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | Pharmaceutical Preparations | OPT+S | $75.55 | 22,321 | $1,686,302 | 11,014 | -67.0% |
| 2026-04-02 22:53 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Director | Pharmaceutical Preparations | OPT+S | $25.00 | 3,000 | $75,000 | 6,200 | -32.6% |
| 2026-04-02 22:54 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $26.27 | 75,000 | $1,970,520 | 705,051 | -9.6% |
| 2026-04-02 22:56 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer; CLO & Secretary | Pharmaceutical Preparations | OPT+S | $201.24 | 5,000 | $1,006,224 | 41,382 | -10.8% |
| 2026-04-02 23:02 | 2026-04-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer; Chief Legal Officer | Pharmaceutical Preparations | SALE | $15.24 | 8,148 | $124,149 | 26,453 | -23.5% |
| 2026-04-02 22:15 | 2026-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer; Chief Medical Officer | Pharmaceutical Preparations | SALE | $52.75 | 942 | $49,693 | 105,673 | -0.9% |
| 2026-04-02 22:19 | 2026-04-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $20.97 | 4,683 | $98,203 | 80,351 | -5.5% |
| 2026-04-02 21:02 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | Pharmaceutical Preparations | BUY | $18.63 | 3,768 | $70,198 | 426,736 | +0.9% |
| 2026-04-02 21:05 | 2026-04-02 | LPCN | Lipocine Inc. | Patel Mahesh V. | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $2.02 | 25,000 | $50,500 | 135,679 | +22.6% |
| 2026-04-02 20:48 | 2026-03-31 | MLTX | MoonLake Immunotherapeutics | BVF PARTNERS L P/IL | Director, 10% owner | Pharmaceutical Preparations | SALE | $16.79 | 3,750,000 | $62,962,500 | 1,039,238 | -78.3% |
| 2026-04-02 20:34 | 2026-03-31 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $585.76 | 9,500 | $5,564,709 | 40,513 | -19.0% |
| 2026-04-02 20:35 | 2026-04-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $581.63 | 9,500 | $5,525,526 | 40,513 | -19.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.